OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs. <\/p>\n
The ChatGPT maker said Thursday that the model, GPT-Rosalind, is intended for life sciences research, such as helping glean insights from large volumes of data and turning scientific studies into health-care applications for patients. The model will be available initially as a research preview to some of the company\u2019s business customers, OpenAI said. The initial users include drugmaker Amgen Inc., vaccine maker Moderna Inc. and the Allen Institute, a bioscience research nonprofit.<\/p>\n
OpenAI, Anthropic PBC and Alphabet Inc.\u2019s Google have increasingly focused on scientific and health-care applications for AI, ranging from using the technology to help guide research on new drugs to having it review personal medical data. In 2024, two Google DeepMind scientists shared the Nobel Prize in chemistry for AlphaFold, an AI system that predicts protein structures. The technology is generally seen as nascent but promising, and some drugs discovered with the help of AI have been involved in early clinical trials.<\/p>\n
Joy Jiao, who leads OpenAI\u2019s life science research, said the company hopes the model can act as a research partner for businesses using it, particularly for biology work that is increasingly reliant on computers. Though OpenAI doesn\u2019t yet believe AI can be used on its own to come up with new treatments for diseases, \u201cwe do think there\u2019s a real opportunity to help researchers move faster through some of the most complex and time-intensive parts of the scientific process,\u201d she said in a briefing with reporters. <\/p>\n
Shares of companies involved in drug discovery fell sharply on the news of OpenAI\u2019s model. IQVIA Holdings Inc. dropped as much as 3.2% while Charles River Laboratories International Inc. slipped 2.6%. Recursion Pharmaceuticals Inc. and Schrodinger Inc. each fell more than 5%.<\/p>\n
OpenAI and rival Anthropic have been racing to develop more advanced AI models that can take on a wider range of tasks, including coding, science and cybersecurity, with the hope of convincing more businesses the technology will save time and money. But as their technology has improved in certain areas, most notably software development, there have been renewed concerns about how AI could be misused, including to create biological weapons.<\/p>\n
Yunyun Wang, OpenAI\u2019s life sciences product lead, said that in addition to evaluating whether organizations can safely use its new model, the company includes \u201chigh-precision flags\u201d if a user hits certain indicators or thresholds related to bioweapons.<\/p>\n
Metz writes for Bloomberg.<\/p>\n","protected":false},"excerpt":{"rendered":"OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery, joining…\n","protected":false},"author":2,"featured_media":6831,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,1479,25,6232,1941,132,6230,6231,6233,527,6234,157,52,5214,882,134],"class_list":{"0":"post-6830","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ai","8":"tag-ai","9":"tag-anthropic-pbc","10":"tag-artificial-intelligence","11":"tag-business-customer","12":"tag-drug-discovery","13":"tag-google","14":"tag-health-care-application","15":"tag-initial-user","16":"tag-life-science-research","17":"tag-model","18":"tag-new-ai","19":"tag-openai","20":"tag-research","21":"tag-share","22":"tag-tech-company","23":"tag-technology"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/6830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=6830"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/6830\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/6831"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=6830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=6830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=6830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}